Catalog No: V29026
CAS No. (CAS Registry Number): 866893-90-5
Description:

Aftin-4 is an Amyloid-β42 (Aβ42) inducer.

Catalog No: V9037
CAS No. (CAS Registry Number): 4429-63-4
Description:

Tabersonine is a naturally occuring terpene indole alkaloid extracted from the medicinal plant Catharanthus roseus and also in the genus Voacanga.

Catalog No: V2021
CAS No. (CAS Registry Number): 517-28-2
Description:

Hematoxylin (also known as Hydroxybrazilin; Natural Black 1) is a natural compound that forms strongly colored complexes with certain metal ions, notably Fe(III) and Al(III) salts and a kind of stain in histology.

Catalog No: V1315
CAS No. (CAS Registry Number): 81065-76-1
Description:

EUK 134 (EUK-134; EUK134), a synthetic and cell permeable superoxide dismutase (SOD)/catalase mimetic, is a novel antioxidant compound that exhibits potent antioxidant activities.

Catalog No: V24107
CAS No. (CAS Registry Number): 58749-23-8
Description:

Licochalcone B, a naturally occuring chalcone compound isolated from the root of Glycyrrhiza inflate, is an inhibitor of phosphorylation of NF-kappaB p65 in LPS signaling pathway.

Catalog No: V18783
CAS No. (CAS Registry Number): 1193447-34-5
Description:

CRANAD-2 is a difluoroboron-based curcumin acting as a near-infrared (NIR) Aβ plaque-specific fluorescent probe for in vivo detection of amyloid-beta deposits.

Catalog No: V2810
CAS No. (CAS Registry Number): 945714-67-0
Description:

FPS-ZM1 is a potent and high-affinity RAGE specific blocker with Ki value of 25 nM.

Catalog No: V4637
CAS No. (CAS Registry Number): 102212-26-0
Description:

ARN2966 is a novel and potent post-transcriptional modulator of APP (amyloid precursor protein) expression; reduces expression of APP with resultant lower production of Aβ.

Catalog No: V2883
CAS No. (CAS Registry Number): 603148-36-3
Description:

Azeliragon (also known as TTP488 and PF-04494700) is a potent and orally bioavailable RAGE (Receptor for Advanced Glycation End products) inhibitor that has the potential for the treatment of mild-to-moderate Alzheimer’s disease and cerebral amyloid angiopathy.